Achondroplasia (ACH) studies

Achondroplasia (ACH) is the most common form of dwarfism. It is caused by a mutation in the FGFR3 gene, which plays an important role in regulating bone growth.

A number of studies are currently being conducted at the University of Auckland to improve the understanding of ACH and to explore potential treatment approaches. Researchers are investigating strategies to enhance bone growth and reduce the health complications associated with this condition.

Individuals with ACH may experience a range of complications, including respiratory difficulties, back and lower limb pain, and recurrent ear infections, which may contribute to hearing loss and speech delay. 

C-type natriuretic peptide (CNP) is an endogenous peptide that contributes to the regulation of bone growth. It has been shown to counteract the effects of FGFR3 overactivity and may support improved skeletal development.

However, CNP has a short half-life in the body, which limits its therapeutic application. Current research is therefore focused on developing longer-acting forms to enhance its effectiveness.

One investigational approach is Navepegritide, a long-acting CNP analogue currently under study for the treatment of achondroplasia. It is designed to provide sustained activity in the body and improve therapeutic outcomes.